University of Liverpool researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to improve patient access and reduce NHS costs.
Anna Forsberg, Professor of Transplant Nursing at Lund University and Chair of the ETAHP Committee at the ESOT, explores a key area of development in heart transplant nursing as part of the build-up to ESOT Congress 2021.
A new study revealing how ovarian cancer cells adapt to their environment to aid tumour growth brings researchers closer to developing targeted treatments.
Damaged heart muscle is a tragic possibility for patients of breast cancer chemotherapy - but thanks to Dr Husam Abdel-Qadir, there may now be a way to stop it.
Salk Institute scientists believe they have solved this mystery for bipolar disorder patients - the answer involves a specific gene, and proposes changes to the future of treatment.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
Frank F Vincenzi, Professor Emeritus, University of Washington, tells us about the mammalian dive response (MDR), drawing on the case of the woman who developed a fatal heart rhythm while SCUBA diving.
In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Michelle Vickers, CEO of the Head and Neck Cancer Foundation tells us what we need to know about head and neck cancer treatment, including comment on driving surgical-technological development.
When it comes to HIV risks for women, researchers found that natural disasters force vulnerable women to take any chance to secure resources - whether through transactional sex or engagement in early marriage.
According to the American Heart Association, women face a stronger heart attack risk than men - they are 20% more likely to develop heart failure, and to die.
Teva and Cephalon faced the €60.5 million antitrust fine, after both companies were found to be actively suppressing the existence of cheaper medicine.
The European Centre for Disease Control (ECDC) and the World Health Organisation (WHO) found that HIV testing in Europe is not good enough - 53% of diagnosis happens when the immune system is already failing.
